KalVista Pharmaceuticals (KALV) Retained Earnings (2014 - 2025)
KalVista Pharmaceuticals recorded quarterly Retained Earnings of -$6.4 million in Q3 2025, up 99.02% quarter-over-quarter from -$653.2 million in Q2 2025, and down 122.62% year-over-year from $28.2 million in Q3 2024.
KalVista Pharmaceuticals' Retained Earnings history runs 12 years deep, the most recent figure standing at -$6.4 million for Q3 2025.
- In Q3 2025, Retained Earnings fell 122.62% year-over-year to -$6.4 million; the TTM figure through Jul 2025 stood at -$6.4 million (down 122.62% YoY), while the FY2025 annual figure was -$653.2 million, down 18626.2% from the prior year.
- Retained Earnings came in at -$6.4 million for Q3 2025 at KalVista Pharmaceuticals, up from -$653.2 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$1.4 million in Q2 2021 to a low of -$653.2 million in Q2 2025.
- A 5-year average of -$125.1 million and a median of -$5.3 million in 2022 frame the typical range for Retained Earnings.
- Across the five-year window, Retained Earnings soared 99.32% in 2024 and sank 18626.2% in 2025, its largest moves.
- KalVista Pharmaceuticals' Retained Earnings stood at -$203.6 million in 2021, then surged by 97.38% to -$5.3 million in 2022, then plunged by 7335.22% to -$396.0 million in 2023, then soared by 99.39% to -$2.4 million in 2024, then tumbled by 164.14% to -$6.4 million in 2025.
- According to Business Quant data, Retained Earnings over the past three periods registered -$6.4 million, -$653.2 million, and -$2.4 million for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | -6.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -6.39 Mn |
| Apr 30, 2025 | -653.17 Mn |
| Dec 31, 2024 | -2.42 Mn |
| Oct 31, 2024 | -2.70 Mn |
| Jul 31, 2024 | -2.87 Mn |
| Apr 30, 2024 | -3.49 Mn |
| Jan 31, 2024 | -3.29 Mn |
| Oct 31, 2023 | -396.00 Mn |
| Jul 31, 2023 | -2.89 Mn |
| Apr 30, 2023 | -3.06 Mn |
| Jan 31, 2023 | -3.54 Mn |
| Oct 31, 2022 | -5.33 Mn |
| Jul 31, 2022 | -273.22 Mn |
| Apr 30, 2022 | -250.18 Mn |
| Jan 31, 2022 | -226.06 Mn |
| Oct 31, 2021 | -203.60 Mn |
| Jul 31, 2021 | -183.90 Mn |
| Apr 30, 2021 | -1.43 Mn |
| Jan 31, 2021 | -152.88 Mn |
| Oct 31, 2020 | -1.96 Mn |
| Jul 31, 2020 | -1.62 Mn |
| Apr 30, 2020 | -121.59 Mn |
| Jan 31, 2020 | -1.38 Mn |
| Oct 31, 2019 | -115.00 Mn |
| Jul 31, 2019 | -1.99 Mn |
| Apr 30, 2019 | -1.93 Mn |
| Jan 31, 2019 | -2.10 Mn |
| Oct 31, 2018 | -79.99 Mn |
| Jul 31, 2018 | -76.69 Mn |
| Apr 30, 2018 | -1.11 Mn |
| Jan 31, 2018 | -71.00 Mn |
| Oct 31, 2017 | -65.77 Mn |
| Jul 31, 2017 | -2.53 Mn |
| Apr 30, 2017 | -2.64 Mn |
| Jan 31, 2017 | -51.65 Mn |
| Mar 31, 2016 | -79.23 Mn |
| Dec 31, 2015 | -72.62 Mn |
| Sep 30, 2015 | -66.96 Mn |
| Jun 30, 2015 | -61.97 Mn |
| Mar 31, 2015 | -52.96 Mn |
| Dec 31, 2014 | -47.78 Mn |